

Bob LÃ¶wenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1908095/publications.pdf>

Version: 2024-02-01

143
papers

22,521
citations

44444

50
h-index

27587

110
g-index

145
all docs

145
docs citations

145
times ranked

21027
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood</i> , 2022, 139, 2347-2354.	0.6	131
2	Overall survival by <i>IDH2</i> mutant allele (R140 or R172) in patients with late-stage mutant- <i>IDH2</i> relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 7005-7005.	0.8	3
3	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
4	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. <i>Blood</i> , 2022, 140, 1345-1377.	0.6	805
5	Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. <i>Blood</i> , 2021, 137, 1792-1803.	0.6	123
6	<i>RUNX1</i> germline variants in <i>RUNX1</i> -mutant AML: how frequent?. <i>Blood</i> , 2021, 137, 1428-1431.	0.6	15
7	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	0.6	183
8	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. <i>Cancers</i> , 2021, 13, 672.	1.7	7
9	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	2.5	33
10	PPM1D mutations appear in complete remission after exposure to chemotherapy without predicting emerging AML relapse. <i>Leukemia</i> , 2021, 35, 2693-2697.	3.3	2
11	Towards precision medicine for AML. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 577-590.	12.5	138
12	Sex disparity in acute myeloid leukaemia with <i>FLT3</i> internal tandem duplication mutations: implications for prognosis. <i>Molecular Oncology</i> , 2021, 15, 2285-2299.	2.1	11
13	Professor Anton Hagenbeek 1948â€“2021: Father of MRD and lymphoma expert. <i>Bone Marrow Transplantation</i> , 2021, 56, 2038-2039.	1.3	0
14	DNA vs cDNA <i>FLT3</i> -ITD allelic ratio and length measurements in adult acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4476-4479.	2.5	4
15	Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation. <i>Blood</i> , 2021, 138, 1276-1276.	0.6	1
16	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	1.1	6
17	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	2.5	85
18	Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia. <i>Cancers</i> , 2020, 12, 3134.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. <i>Blood Advances</i> , 2020, 4, 4267-4277.	2.5	14
20	The long road: improving outcome in elderly "œunfit" AML?. <i>Blood</i> , 2020, 135, 2114-2115.	0.6	2
21	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
22	NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia. <i>Scientific Reports</i> , 2020, 10, 10315.	1.6	5
23	Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 16-18.	0.6	12
24	Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab. <i>Blood</i> , 2020, 136, 19-21.	0.6	5
25	Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123-CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-28.	0.6	1
26	<i>TP53</i> Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
27	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	0.6	21
28	Introduction to a review series on myelodysplastic syndromes. <i>Blood</i> , 2019, 133, 1001-1001.	0.6	4
29	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. <i>Blood</i> , 2019, 133, 1630-1643.	0.6	393
30	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 1146-1155.	0.6	12
31	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. <i>Blood</i> , 2019, 133, 1140-1151.	0.6	96
32	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. <i>Blood</i> , 2019, 133, 1457-1464.	0.6	125
33	An analysis of the impact of CD56 expression in <i>de novo</i> acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. <i>Leukemia and Lymphoma</i> , 2019, 60, 1030-1035.	0.6	9
34	CD34+CD38~ leukemic stem cell frequency to predict outcome in acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1102-1112.	3.3	130
35	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123-CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 460-460.	0.6	2
36	Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2019, 134, 733-733.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy. Blood, 2019, 134, 5144-5144.	0.6	4
38	Clinical and Functional Studies Reveal That TP73 Isoforms Levels Are Associated with Prognosis and RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 2719-2719.	0.6	0
39	Arsenic Trioxide Abrogate MN1 Mediated RA-Resistance in Acute Promyelocytic Leukemia. Blood, 2019, 134, 5166-5166.	0.6	0
40	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 1189-1199.	13.9	605
41	Including historical data in the analysis of clinical trials: Is it worth the effort?. Statistical Methods in Medical Research, 2018, 27, 3167-3182.	0.7	93
42	Reply to "Response to proposal for a novel cancer drug pricing model". Nature Reviews Clinical Oncology, 2018, 15, 528-529.	12.5	0
43	MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood, 2018, 132, 1526-1534.	0.6	90
44	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood, 2018, 131, 2661-2669.	0.6	313
45	Sustainability and affordability of cancer drugs: a novel pricing model. Nature Reviews Clinical Oncology, 2018, 15, 405-406.	12.5	55
46	Reply to "Economic comments on proposal for a novel cancer drug pricing model". Nature Reviews Clinical Oncology, 2018, 15, 588-588.	12.5	1
47	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 2442-2443.	13.9	7
48	Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 – CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 444-444.	0.6	18
49	Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy. Blood, 2018, 132, 2738-2738.	0.6	9
50	Phase 1 Cohort Expansion of Flotetuzumab, a CD123–CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2018, 132, 764-764.	0.6	32
51	Feasibility of HSCT vs consolidation therapy for AML patients aged 60-75 in CR1: A randomized phase III, multicentre EBMT study.. Journal of Clinical Oncology, 2018, 36, 7045-7045.	0.8	0
52	Slit-Robo Pathway Is Clinically Relevant and May Represent a Potential Target in Acute Promyelocytic Leukemia. Blood, 2018, 132, 1533-1533.	0.6	0
53	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood, 2017, 129, 1636-1645.	0.6	77
54	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	0.6	4,375

#	ARTICLE	IF	CITATIONS
55	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. <i>JCO Precision Oncology</i> , 2017, 1, 1-13.	1.5	14
56	Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1807-1814.	2.5	8
57	The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study. <i>Blood Advances</i> , 2017, 1, 86-89.	2.5	0
58	Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2017, 130, 637-637.	0.6	49
59	Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML. <i>Blood</i> , 2017, 130, LBA-5-LBA-5.	0.6	10
60	Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. <i>Haematologica</i> , 2016, 101, e284-e286.	1.7	18
61	MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. <i>Blood</i> , 2016, 128, 2253-2257.	0.6	34
62	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
63	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016, 22, 792-799.	15.2	322
64	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	0.6	0
65	DNMT3A Mutations Enhance CpG Mutagenesis through Deregulation of the Active DNA Demethylation Pathway. <i>Blood</i> , 2016, 128, 1076-1076.	0.6	1
66	Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. <i>Blood</i> , 2015, 125, 133-139.	0.6	86
67	How I treat the older patient with acute myeloid leukemia. <i>Blood</i> , 2015, 125, 767-774.	0.6	177
68	Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2461-2466.	0.6	71
69	High $\hat{1}^{Np73}/TAp73$ ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
70	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , 2015, 100, e409-e411.	1.7	10
71	Dick W. van Bekkum, 1925-2015. <i>Transplantation</i> , 2015, 99, 2442-2443.	0.5	0
72	Dirk Willem van Bekkum: a pioneer in haematology, transplantation and radiobiology (1925-2015). <i>Leukemia</i> , 2015, 29, 2275-2276.	3.3	3

#	ARTICLE	IF	CITATIONS
73	All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. <i>Annals of Hematology</i> , 2015, 94, 1347-1356.	0.8	31
74	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2985-2994.	0.6	42
75	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 2547-2547.	0.6	42
76	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 306-306.	0.6	2
77	Prognostic impact of <i>KMT2E</i> transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. <i>British Journal of Haematology</i> , 2014, 166, 540-549.	1.2	13
78	Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e107587.	1.1	164
79	Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. <i>Annals of Hematology</i> , 2014, 93, 2001-2010.	0.8	58
80	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. <i>Cell</i> , 2014, 157, 369-381.	13.5	571
81	Extensive Molecular Analysis Strongly Improves the Distinction Between AML and ALL in Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , 2014, 124, 1067-1067.	0.6	0
82	Defects in the RAS/RTK Signaling Pathways Predominate the Mutational Spectrum of EVI1/GATA2 Rearranged Myeloid Malignancies with Inv(3)/t(3;3). <i>Blood</i> , 2014, 124, 701-701.	0.6	0
83	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. <i>Blood</i> , 2014, 124, 3676-3676.	0.6	0
84	Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. <i>Blood</i> , 2013, 121, 26-28.	0.6	143
85	A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. <i>Experimental Hematology and Oncology</i> , 2013, 2, 7.	2.0	8
86	High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3889-3897.	0.8	392
87	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	0.6	96
88	Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2516-2516.	0.6	0
89	Outcome Of Patients With Abn(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 303-303.	0.6	0
90	PLI.1 Is Essential For MLL Leukemia Via Activation Of The Meis/HOX Pathway and A Monocytic Cytokine Mediated Anti-Apoptotic Inflammatory Program. <i>Blood</i> , 2013, 122, 1276-1276.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013, 122, 64-64.	0.6	2
92	Prognostic Impact Of MLL5 transcript Levels On Outcome Of Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study. <i>Blood</i> , 2013, 122, 2586-2586.	0.6	0
93	miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. <i>Nature Communications</i> , 2012, 3, 688.	5.8	138
94	Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. <i>Blood</i> , 2012, 119, 5367-5373.	0.6	85
95	The HOXA/PBX3 Pathway Is an Attractive Therapeutic Target in MLL-Rearranged Acute Leukemia. <i>Blood</i> , 2012, 120, 3522-3522.	0.6	0
96	The Gene Encoding Nuclear Erythroid Factor 2 (NFE2) Is Recurrently Mutated in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1392-1392.	0.6	0
97	BAALC and EVI1 Prognostic Gene Expression in Adult Acute Myeloid Leukemia Using the Amlprofiler Custom Microarray. <i>Blood</i> , 2012, 120, 1420-1420.	0.6	0
98	Prognostic and Functional Relevance of Aberrant Microrna-9/9* Expression in Acute Myeloid Leukemia.. <i>Blood</i> , 2012, 120, 2542-2542.	0.6	0
99	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	1.7	59
100	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	0.6	112
101	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011, 117, 4561-4568.	0.6	99
102	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	0.6	103
103	Cytarabine Dose for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 1027-1036.	13.9	343
104	Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab. <i>Blood</i> , 2011, 118, 1555-1555.	0.6	1
105	The Growth Factor Independence 1 variant form GF1136N Predisposes to Acute Myeloid Leukemia by Inducing Epigenetic Changes in Oncogenes Such As Hoxa9. <i>Blood</i> , 2011, 118, 223-223.	0.6	10
106	Comparison Between RT-PCR and RQ-PCR for Minimal Residual Disease Detection in Acute Promyelocytic Leukemia: The International Consortium on Acute Promyelocytic Leukemia (IC-APL) Experience,. <i>Blood</i> , 2011, 118, 3552-3552.	0.6	0
107	$\hat{\gamma}$ Np73/TAp73 Expression Ratio Is Associated with Poor Outcome in Acute Promyelocytic Leukemia,. <i>Blood</i> , 2011, 118, 3536-3536.	0.6	0
108	Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML. <i>Blood</i> , 2011, 118, 2030-2030.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40â€“60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. <i>Blood</i> , 2011, 118, 159-159.	0.6	1
110	A Single Microarray Assay for Simultaneous Diagnosis of t(15;17), t(8;21), Inv(16)/t(16;16), NPM1 Type A/B/D Mutation, CEBPA Double Mutation, and Aberrant Expression of BAALC or EVI1 in AML/APL Patients. <i>Blood</i> , 2011, 118, 4876-4876.	0.6	0
111	Activation of a Mir-181-Targeting HOXA-PBX3 Homeobox Gene Signature Is Associated with Adverse Prognosis of Cytogenetically Abnormal Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 236-236.	0.6	0
112	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. <i>Blood</i> , 2011, 118, 1441-1441.	0.6	0
113	Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. <i>Blood</i> , 2010, 115, 2586-2591.	0.6	131
114	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i> , 2010, 115, 5137-5146.	0.6	278
115	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010, 95, 424-431.	1.7	84
116	DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2010, 17, 13-27.	7.7	737
117	Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. <i>Cancer Cell</i> , 2010, 18, 553-567.	7.7	2,328
118	Phase I/II Clinical Study of Tosedostat, an Inhibitor of Aminopeptidases, in Patients With Acute Myeloid Leukemia and Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2010, 28, 4333-4338.	0.8	67
119	High Prognostic Impact of Mixed Chimerism of Blood and Marrow In the First Year After Allogeneic Hematopoietic Stem Cell Transplantation: The Need to Rapidly Establish Complete Donor Chimerism.. <i>Blood</i> , 2010, 116, 3464-3464.	0.6	0
120	CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies. <i>Blood</i> , 2010, 116, 3279-3279.	0.6	0
121	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2009, 361, 1235-1248.	13.9	745
122	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. <i>Blood</i> , 2009, 113, 1875-1891.	0.6	856
123	Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2080-2080.	0.6	5
124	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. <i>Blood</i> , 2009, 114, 6-6.	0.6	11
125	VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.. <i>Blood</i> , 2009, 114, 997-997.	0.6	1
126	DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 707-707.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.. Blood, 2009, 114, 1062-1062.	0.6	1
128	Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype. Journal of Clinical Oncology, 2008, 26, 4791-4797.	0.8	517
129	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008, 112, 3130-3134.	0.6	154
130	Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety. Hematology American Society of Hematology Education Program, 2008, 2008, 1-11.	0.9	89
131	Double, but Not Single, CEBPA mutations Define a Subgroup of Acute Myeloid Leukemia with Favorable Outcome and a Distinct Gene Expression Profile. Blood, 2008, 112, 141-141.	0.6	24
132	Genetic vs. Epigenetic Disruption of the CEBPA Locus Yields Epigenomically and Biologically Distinct Leukemia Phenotypes.. Blood, 2007, 110, 2117-2117.	0.6	1
133	A Two-Gene Classifier for Predicting Response to the Farnesyltransferase Inhibitor Tipifarnib in Acute Myeloid Leukemia.. Blood, 2007, 110, 1445-1445.	0.6	0
134	High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.. Blood, 2007, 110, 4297-4297.	0.6	1
135	Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia. New England Journal of Medicine, 2004, 350, 1617-1628.	13.9	1,232
136	A Novel Subgroup of Poor Prognostic AML with Low CEBPA Expression, CEBPA Promoter Hypermethylation and DNMT3b Overexpression.. Blood, 2004, 104, 418-418.	0.6	1
137	Clinical Useful Prognostic Index for Adult Patients with Acute Myeloid Leukemia in First Relapse.. Blood, 2004, 104, 2011-2011.	0.6	0
138	Acceleration and Enhancement of T-Cell Recovery and Immune Competence by Flt3-Ligand (Flt3L) Following BMT with Low Numbers of Progenitor Cells in Immune Deficient Mice.. Blood, 2004, 104, 47-47.	0.6	1
139	Pathogenetic Significance of Retrovirus-Tagged Mouse Myeloid Leukemia Genes for Human AML.. Blood, 2004, 104, 468-468.	0.6	0
140	Minimal Residual Disease in Chronic Myeloid Leukemia. New England Journal of Medicine, 2003, 349, 1399-1401.	13.9	59
141	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 4642-4649.	0.8	2,425
142	Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid Leukemia. New England Journal of Medicine, 2003, 349, 743-752.	13.9	356
143	Acute myeloid leukemia and acute promyelocytic leukemia. Hematology American Society of Hematology Education Program, 2003, , 82-101.	0.9	26